Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/27/2014US20140086940 Herceptin® adjuvant therapy
03/27/2014US20140086939 Compositions and methods for detecting and treating cancer
03/27/2014US20140086938 Methods of inhibiting tumor growth using ttk antagonists
03/27/2014US20140086918 Methods for Inhibiting Prostate Cancer
03/27/2014US20140086910 Methods of treating or preventing alzheimer's disease using indane acetic acid derivatives
03/27/2014US20140086909 Methods and compositions for the treatment of proliferative disorders
03/27/2014US20140086903 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
03/27/2014US20140086901 Inhibition of Post-Radiation Tumor Growth
03/27/2014US20140086896 Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
03/27/2014US20140086894 Novel Compositions and Uses Thereof
03/27/2014US20140086893 Regimen For Reducing The Appearance Of Thinning Hair
03/27/2014US20140086873 Esters and Malonates of SATE Prodrugs
03/27/2014US20140086872 Methods of Treating a Subject for a Condition
03/27/2014US20140086870 Pyrazole derivatives as jak inhibitors
03/27/2014US20140086866 Methods For Endoscopic Mucosal Resection And Endoscopic Submucosal Dissection
03/27/2014US20140086857 Compositions Comprising Siloxane Polymer
03/27/2014US20140086855 Combined use of a carnosinase inhibitor with l-carnosine or its related substance and a composition containing the same
03/27/2014US20140086847 Dosage form that is safeguarded from abuse
03/27/2014US20140086832 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
03/27/2014DE102012019029A1 Pharmaceutical formulation prepared by dissolving adjuvant in polyethylene glycols, useful for administration of active multiple charged anions e.g. heparin or its derivative, oligosaccharide or polysaccharide and nucleic acid sequence
03/27/2014DE102012018789A1 New N-isopropylcarbamate compound is phospholipase A2 inhibitor, useful for prophylactic and/or therapeutic treatment of diseases e.g. inflammation, psoriasis, cerebral ischemia, Alzheimer's disease, chronic skin diseases and thrombosis
03/27/2014CA2877188A1 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
03/27/2014CA2875302A1 Method and system for treatment of biological tissue
03/26/2014EP2711705A1 Oxidized cardiolipin as a novel pro-inflammatory factor
03/26/2014EP2711704A1 Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
03/26/2014EP2711433A1 Method for predicting effectiveness of angiogenesis inhibitor
03/26/2014EP2711419A1 Cell differentiation inducer and differentiation inducing method
03/26/2014EP2711372A1 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
03/26/2014EP2711371A1 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
03/26/2014EP2711368A1 Benzoxazepin PI3K inhibitor compounds and methods of use
03/26/2014EP2711367A1 New spiroepoxide tetrahydrobenzo-triazoles and -imidazoles and their use as MetAP-II inhibitors
03/26/2014EP2711366A1 Cationic triphenylamine derivatives activable by visible and Infra Red light for inducing and imaging apoptosis in cancer cells
03/26/2014EP2711365A1 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/26/2014EP2711364A1 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/26/2014EP2711354A1 Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates
03/26/2014EP2711050A1 Compound and cosmetic preparation with such a compound
03/26/2014EP2711024A1 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
03/26/2014EP2711017A1 Immunity inducing agent
03/26/2014EP2711015A1 Immunity induction agent
03/26/2014EP2711014A2 Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis
03/26/2014EP2711012A1 Formulations and methods for recovery from dental surgery
03/26/2014EP2711011A1 Panaxadiol-containing composition
03/26/2014EP2711010A1 Pharmaceutical composition
03/26/2014EP2711009A1 Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
03/26/2014EP2711008A1 N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
03/26/2014EP2711007A1 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
03/26/2014EP2711006A1 Product Comprising a Nicotine-Containing Material and an Anti-Cancer Agent
03/26/2014EP2711005A1 Compound dual-release capsule formulation comprised of bromodihydroarteisinin and fe2+ agent
03/26/2014EP2711004A1 Methods for increasing physical capacity of mammalian livestock
03/26/2014EP2711003A2 Compound useful for preventing or treating irritable bowel syndrome and composition including same
03/26/2014EP2711002A2 Patch containing rivastigmine
03/26/2014EP2711000A1 Targeted Liposomes
03/26/2014EP2710999A1 Stable ophthalmic formulations
03/26/2014EP2710893A1 Methods of treating autism spectrum disorders and compositions for same
03/26/2014EP2710113A1 Novel strain of microalga that produces squalene
03/26/2014EP2710043A1 Shark-like chondroitin sulphate and process for the preparation thereof
03/26/2014EP2710023A2 Purine monophosphate prodrugs for treatment of viral infections
03/26/2014EP2710022A2 A use of a composition comprising of acylated steryl glucoside in the manufacture of a product
03/26/2014EP2710018A2 New compounds
03/26/2014EP2710017A2 Macrocycllc therapeutic agents and methods of treatment
03/26/2014EP2710016A1 Regulation of nitric oxide release and biofilm development
03/26/2014EP2710015A1 Polymorph of rifaximin and process for the preparation thereof
03/26/2014EP2710014A1 New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
03/26/2014EP2710010A1 Novel crystalline salts of asenapine
03/26/2014EP2710009A1 Novel crystalline asenapine hydrochloride salt forms
03/26/2014EP2710008A1 Novel crystalline salts of asenapine with organic di-acids and tri-acids
03/26/2014EP2710007A2 Kinase inhibitors
03/26/2014EP2710006A1 Azaindole derivatives as tyrosine kinase inhibitors
03/26/2014EP2710005A1 Tyrosine kinase inhibitors
03/26/2014EP2710004A1 Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
03/26/2014EP2710003A1 Fused bicyclic kinase inhibitors
03/26/2014EP2710002A1 Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
03/26/2014EP2709999A1 Quinazoline-7-ether compounds and methods of use
03/26/2014EP2709998A1 Substituted indole derivatives for the treatment of immunological disorders
03/26/2014EP2709997A1 Inhibitors of bruton's tyrosine kinase
03/26/2014EP2709996A1 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
03/26/2014EP2709993A2 Amorphous mirabegron and processes for crystal forms of mirabegron
03/26/2014EP2709992A1 1,3-oxazines as bace1 and/or bace2 inhibitors
03/26/2014EP2709991A1 Use of cxcr4 antagonists
03/26/2014EP2709990A1 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
03/26/2014EP2709989A1 Quinazoline derivatives for the treatment of viral infections and further diseases
03/26/2014EP2709987A1 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
03/26/2014EP2709986A1 Deuterated derivatives of ivacaftor
03/26/2014EP2709985A1 Amine derivatives as potassium channel blockers
03/26/2014EP2709984A1 New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
03/26/2014EP2709975A1 Prenylated hydroxystilbenes
03/26/2014EP2709729A1 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl]- 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
03/26/2014EP2709674A1 A process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof
03/26/2014EP2709665A1 Treatment of psoriasis
03/26/2014EP2709662A1 Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
03/26/2014EP2709652A1 Pharmaceutical combination for use in the treatment of diabetes type 2
03/26/2014EP2709645A2 Improved peptide pharmaceuticals
03/26/2014EP2709633A1 Method of treatment or prophylaxis of bacterial vaginosis
03/26/2014EP2709632A2 Compositions and methods for the treatment of skin diseases
03/26/2014EP2709631A1 Antagonists of cb1 receptor
03/26/2014EP2709630A1 Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections
03/26/2014EP2709629A1 Novel cancer therapies and methods
03/26/2014EP2709628A2 Treating protein folding disorders with small molecule cftr correctors
03/26/2014EP2709627A1 Induction of immune tolerance by using methotrexate
03/26/2014EP2709626A1 Method for treatment of advanced solid tumors
1 ... 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 ... 7860